ProBioGen and Lava Therapeutics Sign Development and Manufacturing Agreement for Novel Bispecific Molecule
ProBioGen and Lava Therapeutics have announced the closing of a cell line development and manufacturing agreement for Lava’s novel bispecific antibody lead candidate.
Founded in 2016, Lava Therapeutics works on the development of antibody formats for the successful retrieval and activation of the body’s own immune system to effectively kill cancer cells in the tumor microenvironment. Under the agreement and using its CHO.RiGHT™ expression platform, including its recently launched DirectedLuck Transposase technology for generation of stable high-titer cell lines, ProBioGen will conduct cell line development of a γδ T-cell engaging bispecific antibody format. With subsequent process development and GMP manufacturing, this project depicts another full-service program conducted at ProBioGen.